Douglas Jolly dougjoll@pacbell.net & | Dr. Jolly is an internationally recognized pioneer in the field of gene therapy and its industrial application. For most of the last thirty years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development and commercial manufacturing scale-up at the following companies: Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., Advantagene, Inc. and Tocgen Inc., where he advanced the first in vivo application of an integrating retrovirus through global Phase 3 trials. He has published over 125 scientific articles and is an inventor on over 50 issued patents.

Douglas Jolly

Dr. Jolly is an internationally recognized pioneer in the field of gene therapy and its industrial application. For...

Encinitas, California, United States

*50 free lookup(s) per month.

No credit card required.

Douglas Jolly’s Emails [email protected]

Douglas Jolly’s Phone Numbers No phone number available.

Social Media

Douglas Jolly’s Location Encinitas, California, United States

Douglas Jolly’s Expertise Dr. Jolly is an internationally recognized pioneer in the field of gene therapy and its industrial application. For most of the last thirty years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development and commercial manufacturing scale-up at the following companies: Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., Advantagene, Inc. and Tocgen Inc., where he advanced the first in vivo application of an integrating retrovirus through global Phase 3 trials. He has published over 125 scientific articles and is an inventor on over 50 issued patents.

Douglas Jolly’s Current Industry Abintus Bio

Not the Douglas Jolly you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Abintus Bio

Founder & Chief Advisor

Fri May 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) — Present

Tocagen

Co-Founder, Executive VP, Research & Pharmaceutical Development

Wed Aug 01 2007 00:00:00 GMT+0000 (Coordinated Universal Time) — Fri May 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Advantagene

Co-founder, President & COO

Thu Jan 01 2004 00:00:00 GMT+0000 (Coordinated Universal Time) — Tue Jan 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time)

Oxford Biomedica Biomedica Usa

CEO

Mon Jan 01 2001 00:00:00 GMT+0000 (Coordinated Universal Time) — Thu Jan 01 2004 00:00:00 GMT+0000 (Coordinated Universal Time)

Chiron

VP Scientific Affairs CGT

Sun Jan 01 1995 00:00:00 GMT+0000 (Coordinated Universal Time) — Mon Jan 01 2001 00:00:00 GMT+0000 (Coordinated Universal Time)

Viagene

Co-Founder & VP Research

Fri Jan 01 1988 00:00:00 GMT+0000 (Coordinated Universal Time) — Sun Jan 01 1995 00:00:00 GMT+0000 (Coordinated Universal Time)

Skills

Languages

FAQ About Douglas Jolly

Douglas Jolly is located at
Encinitas, California, United States

Douglas Jolly is a
Dr. Jolly is an internationally recognized pioneer in the field of gene therapy and its industrial application. For most of the last thirty years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development and commercial manufacturing scale-up at the following companies: Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., Advantagene, Inc. and Tocgen Inc., where he advanced the first in vivo application of an integrating retrovirus through global Phase 3 trials. He has published over 125 scientific articles and is an inventor on over 50 issued patents. Abintus Bio

Douglas Jolly currently works in the
Abintus Bio

Douglas Jolly specializes in
Dr. Jolly is an internationally recognized pioneer in the field of gene therapy and its industrial application. For most of the last thirty years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development and commercial manufacturing scale-up at the following companies: Viagene, Inc., Chiron Corporation, Oxford BioMedica, Inc., Advantagene, Inc. and Tocgen Inc., where he advanced the first in vivo application of an integrating retrovirus through global Phase 3 trials. He has published over 125 scientific articles and is an inventor on over 50 issued patents.